Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling
Authors
Keywords
-
Journal
MedChemComm
Volume 8, Issue 4, Pages 700-712
Publisher
Royal Society of Chemistry (RSC)
Online
2016-12-15
DOI
10.1039/c6md00560h
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
- (2016) C. A. Dendrou et al. Science Translational Medicine
- Progress toward JAK1-selective inhibitors
- (2015) Christel J Menet et al. Future Medicinal Chemistry
- Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)
- (2015) Xiaoshan Min et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain
- (2015) John S. Tokarski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome
- (2015) Alexandra Y. Kreins et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural basis of recognition of interferon-α receptor by tyrosine kinase 2
- (2014) Heidi J A Wallweber et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition
- (2014) P. J. Lupardus et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors
- (2013) Jun Liang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year
- (2012) F. Vincenti et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility
- (2011) N. Couturier et al. BRAIN
- Ustekinumab
- (2011) Jamie D. Croxtall DRUGS
- Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: Synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis
- (2010) Alaric J. Dyckman et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor
- (2009) Maria Ban et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis
- (2009) A. Oyamada et al. JOURNAL OF IMMUNOLOGY
- A high-throughput bioanalytical platform using automated infusion for tandem mass spectrometric method optimization and its application in a metabolic stability screen
- (2009) Kasia Kieltyka et al. RAPID COMMUNICATIONS IN MASS SPECTROMETRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More